AMGN

May 20, 2012

MD Becker Partners' newsletter covering the life science industry

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

October 23, 2011 By MD Becker Partners 2 Comments

November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.

Filed Under: Articles Tagged With: 2011 Nobel Prize in Medicine, AAPL, Abraxane, Aduro BioTech, Afinitor, Algenpantucel-L, American Cancer Society, AMG 479, Amgen, AMGN, Apple, Astellas Pharma, Bayer Schering Pharma, CELG, Celgene Corporation, Clovis Oncology, CO-101, CRS-207, Eli Lilly, erlotinib, everolimus, gemcitabine, Gemzar, GlobeImmune, hENT1 protein, IMMU, Immunomedics, INFI, Infinity Pharma, IPI-926, islet cell tumors, LLY, neuroendocrine tumors of pancreatic origin, NewLink Genetics Corporation, Novartis, Novartis AG, Oncolytics Biotech, ONCY, pancreatic cancer, pancreatic NET, Patrick Swayze, Ralph Steinman, Seattle Genetics, Steve Jobs, Tarceva, TH-302, THLD, Threshold Pharmaceuticals

Cancer Immunotherapy: A Roundtable Discussion

June 30, 2011 By MD Becker Partners 3 Comments

Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.

Filed Under: Articles Tagged With: AGS-003, Allovectin-7, American Society of Clinical Oncology, Amgen, AMGN, AnGes, Argos Therapeutics, ASCO, AVAX Technologies, Bavarian Nordic, belagenpumatucel-L, BiovaxID, Biovest International, BLP25 liposome vaccine, BVTI, cancer immunotherapy, Cancer Research Institute, CDX-110, Celldex Therapeutics, CRI, GBM, GlaxoSmithKline, glioblastoma, GSK, Lucanix, MAGE-AS ASCI, melanoma, Merck KGA, MVA-MUC1-IL2, Novartis, Novarx, NSCLC, Oncothyreon, OncoVEX(GM-CSF), prostate cancer, PROSTVAC, rindopepimut, Stimuvax, TG4010, transgene, Vical, VICL

Ipilimumab Approval Highlights Immunotherapy Renaissance

March 25, 2011 By MD Becker Partners Leave a Comment

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Filed Under: Articles Tagged With: AGEN, Agenus, Allovectin-7, Amgen, AMGN, Antigenics, AVAX, AVAX Technologies, AVXT.PK, Bavarian Nordic, BIIB, Biogen Idec, BiovaxID, Biovest International, BioVex, BMY, Bristol-Myers Squibb, BVTI, CancerVax, Canvaxin, CDX-110, Celldex Therapeutics, CLDX, Corixa, Dendreon, DNDN, GlaxoSmithKline plc, GMK vaccine, GSK, ipilimumab, Lucanix, MAGE-A3 ASCI, Melacine, MVAX, Novarx, Oncophage, Oncothyreon, OncoVex, ONTY, Oxford BioMedica, PGNX, Progenics Pharmaceuticals, PROSTVAC, Rituxan, rituximab, Stimuvax, TG4010, transgene, Trovax, Vical, VICL, William Coley, Yervoy

Earthquake Highlights Unmet Need for Treating Radiation Sickness

March 13, 2011 By MD Becker Partners 4 Comments

Nuclear power plant Dukovany, Czech republic

Few treatment options exist for exposure to high doses of ionizing radiation over a short period of time, which would be expected following the meltdown of a nuclear reactor and other scenarios.